Google+

June 19-22, 2017 | San Diego, CA

Double Helix Sponsor

loading...

Schedule at a glance

Registration Rates

Join the Mailing List

 

 

BIO Buzz - Official Show Daily, Brought to you by Alexandria

Health Care

Videos

#BIO2016: June 6-9, 2016 in San Francisco
Habib Dable, Bayer at the 2016 BIO International Convention
Laurance Stuntz, Massachusetts eHealth Institute at the 2016 BIO International Convention
Geoffrey Eich, Amgen at the 2016 BIO International Convention
Dr. Jake Reder, Celdara Medical at the 2016 BIO International Convention
Dr. Asha Das, Tocagen at the 2016 BIO International Convention
Lee Jones, Rebiotix at the 2016 BIO International Convention

Articles from BioTechNow

NORD President: Congress must act now to help 15 million sick children

Publish Date: 9/19/2016, Created By: Daniel Seaton


Writing in The Hill, National Organization for Rare Disorders (NORD) President and CEO Peter Saltonstall called upon Congress to act swiftly to maintain an important program encouraging research into treatments for rare pediatric diseases. The Rare Pediatric Priority Review Voucher (PRV) Program is set to expire at the end of the month, unless Congress reauthorizes it. Saltonstall writes: Developing therapies for people with rare diseases is incredibly difficult. Rare diseases are scientifically and medically complex, ...

Read More >

Challenging Entrepreneurs to Heal the World

Publish Date: 8/23/2016, Created By: BIOtechNOW Editor


The healthcare industry needs a refresh! Through improvements in medicine, sanitation and general living conditions, we’ve made great strides at fighting many of the maladies that have plagued humanity for centuries, lowering child mortality rates while increasing life spans by decades. Yet as a consequence of living longer, we’re facing new health issues and the increasing prevalence of chronic conditions and , neurodegenerative,  metabolic and immunological diseases. Despite scientific advancements in many fields, insufficient progress ...

Read More >

The Washington Post Unfairly Attacks The Orphan Drug Act

Publish Date: 8/8/2016, Created By: Jim Greenwood


The Orphan Drug Act has been a tremendous success and addressed a market failure by providing incentives to bring new treatments to those suffering with rare diseases. That’s why I was deeply troubled by Friday’s unfair article in The Washington Post targeting the Orphan Drug Act through selective and unsubstantiated attacks that seem designed to undermine this bipartisan and hugely successful regime that has helped so many patients with rare diseases live longer and healthier ...

Read More >

BIO Releases Points to Consider on Truthful and Non-Misleading Product Communication

Publish Date: 8/4/2016, Created By: BIOtechNOW Editor


Today, BIO releases Points to Consider on Truthful and Non-Misleading Product Communication. This document advances the dialogue on this issue toward achieving the shared aim of getting the right medicine to the right patient at the right time. The current “Information Age” holds significant promise to improve the ability of stakeholders to make well-informed healthcare decisions.  Never before has information about healthcare interventions, including innovative medicines, been so readily available from so many different sources and through ...

Read More >

Take Action: Sarcoma Awareness Month

Publish Date: 7/18/2016, Created By: BIOtechNOW Editor


The pages on the calendar have quickly turned and July is again upon us.  For most, July means freedom from school, a summer vacation, or celebrating our nation’s independence.  But those of us in the sarcoma community know that this month means something else as well.  As we know, July is Sarcoma Awareness Month. Why do we have a Sarcoma Awareness Month?  Simply, sarcoma is still considered to be the “forgotten cancer.”  Our efforts to encourage ...

Read More >

Bloomberg Caught Spreading Another Inaccurate “False Alarm” About Drug Prices

Publish Date: 6/29/2016, Created By: Jim Greenwood


I was deeply disturbed by Bloomberg’s inaccurate report this morning that attempted to examine drug costs. The article claims it “decodes [our industry’s]…pricing practices.” But, in reality, it does no such thing. It fails to take in the full picture of biopharmaceutical successes and failures; admits its “proof” is merely guesstimates from an organization that wasn’t involved in pricing decisions; and in some cases, it just plain gets the facts wrong. First, this article myopically ...

Read More >

Stop Demeaning the Healthy Dialogue Between Doctors and Drug Companies

Publish Date: 6/28/2016, Created By: Jim Greenwood


A recent report in The Wall Street Journal entitled, “Even Cheap Meals Influence Doctors’ Drug Prescriptions, Study Suggests,” attempts to suggest an untoward influence resulting from drug company-sponsored physician education events. After reading the full study, it is clear that the WSJ author not only misinterpreted the conclusions of the study, but completely discounts the role that companies have in educating physicians about their products. Contrary to the author’s point, communication between drug companies and ...

Read More >

PwC Report Finds Medicines Still Small Share of Overall Health Spending

Publish Date: 6/27/2016, Created By: Stacey Matusko


A new report from PwC’s Health Research Institute, Medical Cost Trend: Behind the Numbers 2017, offers evidence that medicines continue to represent a small portion of overall healthcare spending. The report highlighted that half of all medical costs come from hospital spending: 30 percent from hospital inpatient and 19 percent from hospital outpatient. Physicians account for another 30 percent, while prescription drugs account for 17 percent. With this breakdown comes the warning that it is ...

Read More >

Biotech Solutions for Zika

Publish Date: 6/9/2016, Created By: Daniel Seaton


The Zika virus epidemic continues to rage on. Just today, the WHO advised people in Zika affected countries (much of Latin America and the Caribbean) to consider delaying pregnancy, and emerging evidence suggests a broader range of possible complications for babies born to women infected with the virus than was first thought. Solutions are urgently needed, and biotechnology companies are hard at work to contribute. During a Wednesday at the 2016 BIO International Convention, attendees heard from ...

Read More >

Strategic Venture Investing by Large Pharma: Is “Smart Money” Right for Your Company

Publish Date: 6/9/2016, Created By: BIOtechNOW Editor


The strategic venture arms of major biopharma companies like AbbVie, Amgen, Johnson & Johnson and Pfizer offer unique value propositions to early-stage companies and have the flexibility to shape unique deal structures for advancing these partnerships beyond traditional corporate venture capital models. Speakers at a 2016 BIO International Convention panel titled “Strategic Venture Investing by Large Pharma: Is ‘Smart Money’ Right for Your Company?” provided their about how these venture arms fuel innovation in the ...

Read More >

Thank you to our 2016 Sponsors

Double Helix Sponsors

Helix Sponsors

Premier Sponsors